Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
News | Nuclear Imaging
Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

Time August 04, 2021
arrow
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
News | Prostate Cancer
New AI Tech for Early Detection of Prostate Cancer

July 19, 2021 — Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men ...

Time July 19, 2021
arrow
Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.
News | Prostate Cancer
MRI Can Cut Over-diagnoses in Prostate Cancer Screening by Half

July 12, 2021 — Most countries have not introduced nationwide prostate cancer screening, as current methods result in ...

Time July 12, 2021
arrow
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
News | Prostate Cancer
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

Time June 21, 2021
arrow
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.
News | Prostate Cancer
Decrease in Prostate Cancer Diagnoses Due to Pandemic

April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer ...

Time April 30, 2021
arrow
A new study led by Ivan Martinez—associate professor in the WVU School of Medicine and Cancer Institute—found a link between a family of RNAs, the Y chromosome, and radiation sensitivity in male lung-cancer patients
News | Radiation Therapy
Loss of Y chromosome, RNA Tied to Radiation Resistance in Male Lung-cancer Patients

March 23, 2021 — The science behind the COVID-19 vaccine has the potential to do more than prevent cases of COVID-19 ...

Time March 23, 2021
arrow
A national screening program targeted at those men who are genetically pre-disposed to prostate cancer, and involving a blood test and magnetic resonance imaging (MRI) scan before an invasive biopsy, could prevent one in six prostate cancer deaths and significantly reduce over-diagnosis, finds a new study led by UCL researchers.
News | Prostate Cancer
Targeted Screening for Prostate Cancer Could Prevent One in Six Deaths

March 15, 2021 — A national screening program targeted at those men who are genetically pre-disposed to prostate cancer ...

Time March 15, 2021
arrow
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
Immunotherapy-based precision medicine clinical trials being developed
News | Prostate Cancer
Why Black Men's Prostate Cancer May be More Responsive to Immunotherapy

February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from ...

Time February 16, 2021
arrow
The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million donation from philanthropist Robert F. Smith to launch the Robert F. Smith Mobile MRI Unit in partnership with the Mount Sinai Health System to support prostate health in the Black community.
News | Prostate Cancer
Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community

February 12, 2021 — The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million ...

Time February 12, 2021
arrow
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
News | Magnetic Resonance Imaging (MRI)
Using MRI for Prostate Cancer Diagnosis Equals or Beats Current Standard

February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting ...

Time February 08, 2021
arrow
News | Prostate Cancer
Ultrasound Technique Treats Prostate Cancer with Minimal Side Effects

February 5, 2021 — A technique that delivers high-intensity focused ultrasound to targeted tissue under MRI guidance ...

Time February 05, 2021
arrow
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost, as shown by a large-scale study initiated by UMC Utrecht in collaboration with the Netherlands Cancer Institute, UZ Leuven and Radboudumc.
News | Prostate Cancer
Radiation Boost Lowers Risk of Prostate Cancer Recurrence

January 25, 2021 — An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects ...

Time January 25, 2021
arrow
MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.
Feature | Prostate Cancer | By Brian Wodlinger, Ph.D.
Detecting Prostate Cancer With Advanced Micro-ultrasound

Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next ...

Time January 20, 2021
arrow
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH
News | Coronavirus (COVID-19)
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge

January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses ...

Time January 15, 2021
arrow
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.
News | Prostate Cancer
US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook

January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast ...

Time January 13, 2021
arrow
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.
News | Prostate Cancer
MRI Frequently Underestimates Tumor Size in Prostate Cancer

January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic ...

Time January 11, 2021
arrow
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
News | Prostate Cancer
Radiation Therapy Has the Greatest Impact on Patient Finances

December 2, 2020 — For men with early-stage prostate cancer, choices about initial treatment carry varying risks of ...

Time December 02, 2020
arrow
 Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
News | PET Imaging
Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent in Collaboration with Nucleis Radiopharmaceuticals

November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their ...

Time November 25, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now